Rein Therapeutics
RNTX
30 hedge funds and large institutions have $10.8M invested in Rein Therapeutics in 2020 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 10 closing their positions.
203% more capital invested
Capital invested by funds: $3.58M → $10.8M (+$7.25M)
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
20% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 10
7% more funds holding
Funds holding: 28 → 30 (+2)
0.83% more ownership
Funds ownership: 0.45% → 1.28% (+0.83%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$247K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$108K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$102K |
| 4 |
GPFA
Game Plan Financial Advisors
Westlake,
Ohio
|
+$85.6K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$77.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$712K |
| 2 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$340K |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$196K |
| 4 |
MS
Maven Securities
St Helier,
Jersey
|
-$106K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$56K |
RNTX Hedge Fund Activity: Q4 2020 in Review
30 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Rein Therapeutics (RNTX) for Q4 2020, worth a combined $10.8M — up 203% from $3.58M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new RNTX positions and 10 closed out — a net gain of 2 holders — while 5 added to existing stakes and 4 trimmed.
The largest buyer was Vanguard Group, adding an estimated $247K. The largest seller was Renaissance Technologies, cutting an estimated $712K.
- 30 institutional investors held Rein Therapeutics (RNTX) as of Q4 2020, up from 28 in Q3 2020.
- Funds reported $10.8M of Rein Therapeutics stock for Q4 2020, up 203% quarter-over-quarter.
- 12 funds opened new Rein Therapeutics positions in Q4 2020 and 10 closed out, a net change of +2 holders.
- The largest Rein Therapeutics buyer in Q4 2020 was Vanguard Group, an estimated $247K added.
- The largest Rein Therapeutics seller in Q4 2020 was Renaissance Technologies, an estimated $712K sold.
Based on aggregated 13F filings for Q4 2020.